Charles River Laboratories International, Inc. (CRL): Cash & Equivalents
$213.77M
As of 2025-12-27
$192.03M
As of 2026-06-27
-3.0%
3-year compound annual growth
-1.3%
5-year compound annual growth
+6.1%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | $213.77M | +9.8% | 2026-02-18, Balance as of period end |
| 2024-12-28 | $194.61M | -29.7% | 2026-02-18, Balance as of period end |
| 2023-12-30 | $276.77M | +18.3% | 2025-02-19, Balance as of period end |
| 2022-12-31 | $233.91M | -3.0% | 2024-02-14, Balance as of period end |
| 2021-12-25 | $241.21M | +5.6% | 2023-02-22, Balance as of period end |
| 2020-12-26 | $228.42M | -4.0% | 2023-02-22, Balance as of period end |
| 2019-12-28 | $238.01M | +21.8% | 2022-02-16, Balance as of period end |
| 2018-12-29 | $195.44M | +19.3% | 2021-02-17, Balance as of period end |
| 2017-12-30 | $163.79M | +39.2% | 2020-02-11, Balance as of period end |
| 2016-12-31 | $117.63M | -0.3% | 2019-02-13, Balance as of period end |
| 2015-12-26 | $117.95M | -26.3% | 2018-02-13, Balance as of period end |
| 2014-12-27 | $160.02M | +2.6% | 2017-02-14, Balance as of period end |
| 2013-12-28 | $155.93M | +42.2% | 2016-02-12, Balance as of period end |
| 2012-12-29 | $109.69M | +59.2% | 2015-02-17, Balance as of period end |
| 2011-12-31 | $68.91M | -61.5% | 2014-02-25, Balance as of period end |
| 2010-12-25 | $179.16M | -1.9% | 2013-02-27, Balance as of period end |
| 2009-12-26 | $182.57M | -25.0% | 2012-02-27, Balance as of period end |
| 2008-12-27 | $243.59M | n/a | 2011-02-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $213.77M | +9.8% |
| Incyte Corp (INCY) | 2025-12-31 | $3.10B | +83.5% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $497.05M | -25.8% |
| Icon PLC (ICLR) | 2025-12-31 | $647.29M | +20.1% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $1.98B | +16.3% |
| NRC Health (NRC) | 2025-12-31 | $4.14M | -2.2% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $20.07M | -28.0% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $25.52M | -7.5% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $207.5K | +203.9% |
Compare CRL, INCY, MEDP, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗